Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook
Looking to the future of Alzheimer disease treatment, the panel discusses key takeaways on the evolving therapeutic landscape.
Payer Coverage Considerations for New Treatments for Alzheimer Disease
Experts discuss how payers can prepare for new treatments and plan adequate coverage for patients with Alzheimer disease.
Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden
An overview of how disease-modifying treatments for Alzheimer disease can impact medical costs and caregiver burden.
Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates
The panel discusses emerging therapies for Alzheimer disease that are currently in development, including donanemab, subcutaneous lecanemab, and ALZ-801.
Cost, Value, and Affordability of Treatment for Alzheimer Disease
A comprehensive discussion on the value of therapies for Alzheimer disease based on cost vs outcome, and unmet needs in the overall treatment landscape.
Clinical Decision-Making for Alzheimer Disease Management
Experts provide their perspectives on clinical factors taken into consideration when deciding on a treatment plan for a patient with Alzheimer disease.
Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease
Experts on Alzheimer disease discuss how the introduction of disease-modifying therapies has impacted the treatment landscape.
Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease
The panel provides insights on the economic impact of advanced approaches for diagnosing Alzheimer disease, highlighting how payers approach increased costs.
Criteria for Diagnosing Alzheimer Disease and the Role of Testing
Focusing on the diagnosis of Alzheimer disease, the panel discusses key diagnostic criteria, testing practices, and the role of genetic testing.
Potential Consequences of Early Diagnosis of Alzheimer Disease
B. Joy Snider, MD, PhD, discusses the benefits of early diagnosis of Alzheimer disease and how it can impact the patient journey.
The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease
The expert panel offers comprehensive insights on the patient journey for people with Alzheimer disease, highlighting symptoms, challenges, and the diagnostic process.
Genetic Aspects of Alzheimer Disease
The panel provides an overview of genetic factors associated with Alzheimer disease and the genetic mutations that contribute to the pathophysiology of the disease.
Recent Insights into the Pathophysiology of Alzheimer Disease
B. Joy Snider, MD, PhD, gives an overview of the pathophysiology of Alzheimer disease, highlighting recent advances in the field.
The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System
A panel of experts on Alzheimer disease provide insights on symptoms the patient might experience and the impact of the disease on patients, families, caregivers, and the health care system.
Results From a National Survey on Chronic Care Management by Health Plans
This study shows that health plans use chronic care management programs as standard components of the overall approach to manage the health of their members.
Systematic Review of the Impact of Worksite Wellness Programs
Analysis of studies of worksite wellness programs suggested mixed impact on health-related behaviors and cost, with insufficient evidence regarding absenteeism and mental health.
Adoption and Use of Stand-Alone Electronic Prescribing in a Health Plan-Sponsored Initiative
In a health plan–sponsored e-prescribing initiative, participating PCPs' mean e-prescribing rate was 1 prescription per 4 pharmacy claims, but some PCPs achieved high use.
Impact of 2 Employer-Sponsored Population Health Management Programs on Medical Care Cost and Utilization
Integrated health management programs combining disease prevention and disease management services, although popular with employers, may not save money, at least in their first year.
Is There a Disease Management Backlash?
Recent events have cast doubt on the ability of disease management to reduce medical cost and to affect the quality of care.
Evidence for the Effect of Disease Management: Is $1 Billion a Year a Good Investment?
A Review of Methods to Measure Health-related Productivity Loss
